Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin
Launched by ZIWIG · Aug 22, 2022
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called OVAmiARN, is studying how certain tiny pieces of genetic material found in saliva, known as miRNAs, change in women who have an ovarian mass, which could be ovarian cancer, a borderline tumor, or a benign cyst. The goal of this research is to help doctors diagnose these conditions faster and improve the overall care process for patients. The study is taking place in eight hospitals in France and involves women who need surgery for their ovarian mass. Importantly, the way doctors treat and monitor these patients will not change because of the study; all standard medical procedures will remain the same.
To be eligible for this trial, women must be at least 18 years old and have a diagnosed ovarian mass that requires surgery. Participants will be asked to provide saliva samples at different times before and after their surgery, but their medical care will continue as usual. It is essential to note that pregnant women, those with HIV, or individuals with other active cancers are not eligible to join this study. If you meet the criteria and are interested in contributing to important research that could help many women in the future, this trial might be a great opportunity for you.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patient over 18 years of age,
- • A patient with an ovarian adnexal mass diagnosed by clinical examination and imaging and likely to be ovarian cancer, a borderline tumour or a benign cyst,
- • Patient with an indication for surgery
- • Patient has dated and signed the consent form,
- • Patient affiliated to the healthcare system,
- Exclusion Criteria:
- • Pregnant patient
- • Patient infected with human immunodeficiency virus (HIV),
- • Patient with significant difficulties in reading or writing the French language.
- • Patient with another diagnosed cancer
- • Patient with a history of cancer less than 5 years old
About Ziwig
Ziwig is a pioneering clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on cutting-edge therapies and technologies, Ziwig collaborates with healthcare professionals and institutions to design and execute clinical trials that adhere to the highest standards of scientific integrity and regulatory compliance. Committed to improving patient outcomes, Ziwig leverages a patient-centric approach, ensuring that trials are not only scientifically robust but also aligned with the needs and experiences of participants. Through its expertise and strategic partnerships, Ziwig aims to accelerate the delivery of transformative treatments to market.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nice, , France
Toulouse, , France
Angers, , France
Rennes, , France
Paris, , France
Rennes, , France
Niort, , France
Bastia, , France
Tours, , France
Caen, Calvados, France
Lyon, , France
Paris, , France
Lyon, , France
Rouen, , France
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials